KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsBuildingsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Edwards Lifesciences (EW) Current Leases (2019 - 2025)

Edwards Lifesciences (EW) has 8 years of Current Leases data on record, last reported at $24.5 million in Q4 2025.

  • For Q4 2025, Current Leases rose 4.7% year-over-year to $24.5 million; the TTM value through Dec 2025 reached $24.5 million, up 4.7%, while the annual FY2025 figure was $24.5 million, 4.7% up from the prior year.
  • Current Leases reached $24.5 million in Q4 2025 per EW's latest filing, down from $26.8 million in the prior quarter.
  • Across five years, Current Leases topped out at $26.8 million in Q3 2025 and bottomed at $21.5 million in Q2 2024.
  • Average Current Leases over 5 years is $24.4 million, with a median of $24.3 million recorded in 2023.
  • Peak YoY movement for Current Leases: dropped 11.52% in 2024, then grew 20.47% in 2025.
  • A 5-year view of Current Leases shows it stood at $25.5 million in 2021, then changed by 0.0% to $25.5 million in 2022, then decreased by 10.2% to $22.9 million in 2023, then grew by 2.18% to $23.4 million in 2024, then increased by 4.7% to $24.5 million in 2025.
  • Per Business Quant database, its latest 3 readings for Current Leases were $24.5 million in Q4 2025, $26.8 million in Q3 2025, and $25.9 million in Q2 2025.